MANAGEMENT
Chief Executive Officer
Gerald Baty, J.D., MBA
Mr. Baty has over 20 years of experience in the initiation, funding, development and commercialization of biopharmaceutical and medical device products. Mr. Baty is also a Partner with Newport LLC, providing C-level advisory services to middle-market companies in the areas of event/transaction readiness, management and other transformational events either through a pure advisory role or as an interim or fractional executive. In addition, Mr. Baty has co-founded or has led several companies during their early development, including StitchLock (TM) Inc., Emerald Mobility, a private aviation service, Lantern UAS, a drone-based ESG monitoring company, and Paciolus Group, a DHS IT personnel contractor. Mr. Baty also serves as Chairman of the Board and Compensation Committee member for Seraxis Holdings; member of the Houston Symphony Audit Committee; and member of the Lighthouse for Students Board of Directors. Prior to Brazos Bio, Mr. Baty was the CEO of SafeTech USA, Inc., a nation-wide aviation safety equipment company, which he sold in a Private Equity-backed Strategic transaction. Following the sale, he ran the consolidated U.S. operation for two years. Prior to SafeTech, Mr. Baty served as CFO for several development-stage companies in the pharmaceutical, biotechnology and medical device industries. Mr. Baty holds a J.D. from South Texas College of Law, an M.B.A. from the University of Houston, C.T. Bauer College of Business, and a B.B.A. in Accounting from Stephen F. Austin State University. He is a licensed CPA in Texas and is licensed to practice law in New York.
President, Chief Operating Officer
Kurt L. Berens
Mr. Berens is a Co-Founder of Brazos Biomedical and has over 20 years of experience in the development and commercialization of biopharmaceutical and medical device products. Mr. Berens has been part of development teams that received registration and marketing approval for two ethical drug products [Argatroban® (US), Thelin® (EMEA)] and one medical device [Galileo® System centering catheter and intracoronary brachytherapy system]. Mr. Berens has developed novel drug dosage forms and delivery technology for NASA’s Pharmacotherapeutics Group and served as the Manager for Cellular and Biomedical Section in the Bioastronautics Group at Johnson Space Center in Houston, TX. Mr. Berens served as Senior Project Manager at Texas Biotechnology Corporation and as Vice President, Product Development, at CytoGenix, Inc., (both located in Houston, TX) and Vice President of Product Development at Tuevol Therapeutics, Inc. Most recently, Mr. Berens served as the Executive Director of the Borders, Trade, and Immigration Institute, a Department of Homeland Security Center of Excellence. Mr. Berens received his BA from the University of Minnesota with post-graduate training in Pharmaceutics at the University of Houston.
COMPANY ADVISORS
Medical Scientific Affairs
Ioannis M. Skaribas, M.D.
Dr. Ioannis Skaribas earned his medical degree at Aristotelian University of Thessaloniki Medical School in Greece. He completed a 4-year Anesthesiology residency in Athens Greece, and obtained board certification before moving to the US. In Houston, he completed an internship in anesthesiology and a residency in Anesthesiology at Baylor College of Medicine. During his residency, he received the “Intern of the Year” award. After his residency he completed a ACGME accredited interventional fellowship in pain medicine at Baylor College of Medicine. Double Board certified in Anesthesiology and Pain Medicine, Dr. Skaribas specializes in Interventional Pain therapies. His clinical interests include spinal cord stimulation, and neuromodulation as well as intraspinal interventional therapies and treatment of intractable Headaches. Dr. Skaribas has an appointment as a clinical assistant professor in pain medicine at The University of Texas Health Science Center at Houston, and serves on the board of directors of the Memorial Hermann Sugar Land Surgery Center. He has served as an assistant professor of anesthesiology at BCM. Until March of 2018 he has been a partner physician and shareholder with US Anesthesia Partners. He has served as the medical director of the Pain Management branch of USAP.
Intellectual Property
David Foster, Ph.D., J.D.
Dr. Foster is CEO of Island Pharmaceuticals and is a Co-Founder of Brazos Biomedical. Dr. Foster has over 19 years of experience in the development and commercialization of healthcare products. Dr. Foster is co-founder and an active Board member of BioNorth Texas. Dr. Foster co-founded Roberts Foster LLP, a boutique law firm focused on providing legal services for emerging technology companies. Prior to that, Dr. Foster spent several years in private legal practice providing IP strategy for a number of emerging biotechnology companies. In addition, Dr. Foster served as a patent counsel at Medarex, Inc. where he was an integral member of project teams developing novel checkpoint inhibitor protein biotherapeutics. At Medarex, Dr. Foster provided counsel on IP due diligence and strategic patent prosecution matters that contributed to expansion of the IP portfolio as well as in-licensing of key molecules. Dr. Foster received his BS in Biology from the University of North Texas, his Ph.D. in Cell Regulation from the University of Texas Southwestern Medical Center at Dallas and his JD from Golden Gate University School of Law in San Francisco, CA. Dr. Foster is a member of the patent bar as well as California and Texas state bars